Arecor Therapeutics PLC Arecor Granted Key U.S Patent (4505X)
April 26 2023 - 2:00AM
UK Regulatory
TIDMAREC
RNS Number : 4505X
Arecor Therapeutics PLC
26 April 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF
MONOCLONAL ANTIBODIES
- Endorses potential of proprietary Arestat (TM) platform
technology to invent novel, enhanced therapeutics in $210 billion
monoclonal antibody market
- Further strengthens Group's extensive patent portfolio
Cambridge, UK, 26 April 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, is pleased to announce that the United
States Patent and Trademark Office has granted a patent
(US11608357) protecting a novel formulation platform that enables
the development of enhanced monoclonal antibodies.
Monoclonal antibodies represent a key segment of the
biopharmaceuticals market, valued at $210 billion in 2022 and are
projected to see a compound annual growth rate (CAGR) of 11.04%
from 2023 to 2030(1) .
There has been a strong drive towards patient-centricity in the
biopharmaceutical industry, particularly in the development of
convenient dosage forms. However, achieving such desirable dosage
forms is often hampered by insufficient stability or high viscosity
of monoclonal antibodies when formulated using conventional
formulation approaches. To address this problem Arecor has
developed a number of highly innovative, proprietary formulation
platforms enabling superior stability of monoclonal antibodies
under various stress conditions. This US patent protects one of
these proprietary formulation platforms within the Group's broader
Arestat(TM) technology.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented :
"Whilst a number of novel therapeutic modalities are being
developed, such as complex engineered protein constructs or mRNA
therapies, monoclonal antibodies continue to dominate the
biopharmaceutical field. Safety and efficacy are obviously the key
criteria for any new product, but the increasing focus on
patient-centricity and improved convenience of delivery often
requires superior product stability which is often difficult to
achieve using conventional approaches. Our highly innovative
formulation technology addresses these challenges and, when
applied, we are able to develop enhanced novel pharmaceutical
products, both for our growing partnerships with Pharma companies
and in our proprietary pipeline. This US patent is a very important
addition to our IP portfolio, protecting a formulation design space
that enables monoclonal antibodies with superior stability."
Arecor leverages its Arestat(TM) technology in partnerships with
leading pharmaceutical and biotechnology companies to deliver
enhanced products under a technology licensing model, as well as
developing an internal portfolio of proprietary products in
diabetes and other indications. As part of this strategy Arecor
continues to invest in a strong patent portfolio to protect the
Arestat(TM) platform, currently comprising 38 patent families and
>75 granted patents.
References
1. https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arestat(TM)
Arecor's Arestat(TM) technology enables superior product
profiles across a broad range of therapies, including various types
of biopharmaceuticals and specialty hospital products. In addition
to its internal portfolio of superior proprietary products in
diabetes and other indications, Arecor leverages the Arestat(TM)
technology in partnerships with leading pharmaceutical and
biotechnology companies to deliver enhanced products under a
technology licensing model .
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary technology platform,
Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver therapeutic products. The Arestat (TM) platform is
supported by an extensive patent portfolio .
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAELSAFDDEAA
(END) Dow Jones Newswires
April 26, 2023 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024